Ipratropium/Salbutamol Orion (Salbutamol, Ipratropium Bromide Monohydrate)

The formulation contains salbutamol, a β2‑adrenergic agonist that stimulates β2 receptors on airway smooth muscle, causing relaxation, and ipratropium bromide, an anticholinergic that blocks muscarinic receptors, preventing vagal‑mediated bronchoconstriction. The dual action produces additive bronchodilation, enhancing airflow in obstructed airways.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal bronchodilation while minimizing potential side effects.

Safety in pregnancy and lactation has not been fully established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent bronchodilators, the combination offers additive bronchodilation by targeting both β2‑adrenergic and muscarinic pathways. This can provide more rapid and sustained symptom relief in asthma and COPD, especially in patients who do not achieve adequate control with monotherapy.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain product integrity.

The medication is intended for oral administration as directed by a healthcare professional. It should be taken exactly as prescribed, with or without food, and the patient should follow any specific instructions regarding timing and dosage.

Serious adverse events include paradoxical bronchospasm, significant cardiac arrhythmias, severe tachycardia, hypersensitivity reactions such as angioedema, and marked hyperglycaemia in susceptible individuals. Patients should seek immediate medical attention if they experience any of these symptoms.

Patients with known hypersensitivity to salbutamol, ipratropium bromide, or any excipients in the formulation should avoid this product. Additionally, individuals with certain cardiac conditions, uncontrolled hypertension, or severe hyperthyroidism should use it only under close medical supervision.